A rare cause of healthcare-associated infective endocarditis: Enterobacter cloacae

Recurrent Infective Endocarditis of the Mitral Valve after Orthotopic Heart Transplantation

Introduction

Orthotopic heart transplantation is the gold standard for the treatment of advanced heart failure in the absence of contraindications. Infective endocarditis is a rare complication in patients after heart transplantation. The treatment of endocarditis after heart transplantation is challenging since there is a need for ongoing immunosuppression.

Case description

We present the case of a 51-year-old orthotopic heart transplant recipient enrolled in a chronic dialysis program, in whom we diagnosed and successfully treated recurrent infective endocarditis of the mitral valve caused by Enterococcus and Enterobacter species. Despite the complicated course of the disease, the treatment was successful.

Conclusions

Recurrent infective endocarditis after heart transplantation can be treated successfully with a multidisciplinary approach and robust antimicrobial therapy.

LEARNING POINTS

There is a high risk of bacteraemia and subsequent endocarditis in patients with recurrent catheter-related sepsis.The spectrum of bacteria causing endocarditis in patients after heart transplantation differs from that in the general population.Scrupulous targeted antibiotic treatment is warranted for the treatment of immunosuppressed patients with endocarditis.

Phenotypic and genomic insights into the pathogenicity and antimicrobial resistance of an Enterobacter roggenkampii strain isolated from diseased silver arowana (Osteoglossum bicirrhosum)

Enterobacter roggenkampii is an opportunistic pathogen that causes infections in a wide range of hosts. A bacterial strain named EOBSR_19 was isolated from diseased silver arowana, Osteoglossum bicirrhosum. This bacterium was identified as E. roggenkampii based on the phenotypic characteristics and sequence analysis of the16S rDNA and gyrB genes. Average nucleotide identity and phylogenetic analysis based on the whole genome sequence further confirmed the bacterial taxonomy of EOBSR_19. Artificial experimental infection indicated that EOBSR_19 was pathogenic to fish. Antimicrobial susceptibility test showed it was multi-drug resistant. The EOBSR_19 was found to be resistant to 18 antibiotics belonging to quinolones, macrolides, sulfonamides, aminoglycosides, and β-lactams classes. The whole genome sequencing analysis showed that EOBSR_19 carried 730 virulence genes that were annotated for different functional modules, such as adhesion and invasion, secretion system, siderophore transport system and bacterial toxin. Among them, the virulence genes related to adhesion and invasion were the most abundant. In addition, drug resistance genes involved in multiple mechanisms of antimicrobial resistance were identified in its genomics, including multidrug resistance efflux pumps, antibiotic inactivating enzymes, and antibiotic binding site mutations. Its genomic analysis via whole-genome sequencing provided insights into the pathogenicity and antimicrobial resistance.

Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii

OBJECTIVES

The Enterobacter cloacae complex is responsible for a variety of infections in hospitalized patients and is resistant to β-lactam antibiotics owing to the expression of AmpC β-lactamase. We report emerging resistance in Enterobacter roggenkampii exposed to ceftriaxone and explore the mechanism underlying mutations responsible for this resistance.

METHODS

Three strains were derived from different samples from one patient (blood and liver abscess fluid). Antimicrobial susceptibility was evaluated by standard broth microdilution, while ampC expression was determined via RT-PCR. Genetic relatedness was evaluated via pulsed-field gel electrophoresis (PFGE). Species identification and comparative genome analysis were performed via genome sequencing. Mutation rate testing and selection of AmpC-derepressed mutants were conducted to explore the mutation mechanism.

RESULTS

E. roggenkampii F1247 was susceptible to third-generation cephalosporins (3GCs); F95 and F1057, found in blood sample on day 11 and liver abscess drainage fluid on day 25, were resistant. ampC expression was 341- and 642-fold higher in F95 and F1057, respectively, than in F1247. Three isolates were the same PFGE and sequence types (ST1778) and were highly homologous (2 and 4 core genome single nucleotide polymorphism differences). Compared to F1247, F95 possessed a 575 bp deletion, including 537 bp of ampD, whereas F1057 harbored only one amino acid mutation (Leu140Pro in ampD). The mutation rates from F1247 exposure to cefotaxime, ceftazidime, ceftriaxone, piperacillin-tazobactam, and cefepime were (1.90 ± 0.21) × 10^-8, (3.18 ± 0.43) × 10^-8, (2.00 ± 0.20) × 10^-8, (2.92 ± 0.29) × 10^-9, and zero, respectively. In vitro-selected mutations responsible for resistance were identified in ampD, ampR, and dacB.

CONCLUSIONS

E. roggenkampii may develop resistance in vivo and in vitro upon exposure to 3GCs and to a lesser extent to piperacillin-tazobactam. 3GCs should not be used as a monotherapy for E. roggenkampii infections. Therapy using cefepime or carbapenems may be preferred to piperacillin-tazobactam in the treatment of E. roggenkampii, especially if source control is difficult.

Infective endocarditis by Enterobacter cloacae: a systematic review and meta-analysis

Enterobacter species are Gram-negative, non-spore-forming, facultative anaerobes typically motile due to the presence of peritrichous flagella. E. cloacae, the species responsible for the majority of Enterobacter infections in humans, is part of the intestinal microbiota and may cause infection in patients that have previously received antimicrobial therapy or who have been admitted to the Intensive Care Unit. E. cloacae may cause several infections, such as pneumonia, urinary tract, skin and soft tissue and intravascular infections. Infective Endocarditis (IE) is a rare disease with notable morbidity and mortality. Even though IE is rarely caused by E. cloacae, these infections can be problematic due to the relative lack of experience in their management. The purpose of this study was to systematically review all published cases of IE by E. cloacae in the literature. A systematic review of PubMed, Scopus and Cochrane library (through 14^th November 2020) for studies providing epidemiological, clinical, microbiological as well as treatment data and outcomes of IE by E. cloacae was performed. A total of 20 studies, containing data of 20 patients, were included. A prosthetic valve was present in 27.8%. Mitral valve was the commonest infected site, followed by aortic valve. Diagnosis was facilitated by transthoracic and transesophageal echocardiography in 38.5% each, while the diagnosis was set at autopsy in 10%. Fever, sepsis, shock and immunologic phenomena were the most common clinical presentations, followed by heart failure. Aminoglycosides, cephalosporins and carbapenems were the most common antimicrobials used. Clinical cure was noted in 75%, while overall mortality was 30%. Development of shock and treatment with the combination of piperacillin with tazobactam were associated with overall mortality.

Elusive Enterobacter cloacae causing pacemaker endocarditis

An 80-year-old patient was admitted for fever, chills, and chest wall pain. He had a past medical history significant for heart failure with a cardiac resynchronization therapy pacemaker implantation. Extensive workup revealed Enterobacter cloacae endocarditis of the pacemaker leads and the mitral valve, a rare etiology with an unidentified source in our patient. He was managed with a rather unconventional method which proved to be successful. This case sheds light on non-HACEK (other than Haemophilus spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, or Kingella spp). gram-negative organisms, and particularly E. cloacae, as uncommon causes of endocarditis with elevated mortality, and discusses potential treatment modalities.

RETRACTED: Antibacterial and antibiofilm activity of ursolic acid against carbapenem-resistant Enterobacter cloacae

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request ofthe corresponding author and the editor-in-chief. The authors have notified the journal that Fig. 3E and 3F in this article was a duplicate image of Fig. 3C of the article published by Weidong Qian, Miao Liu, Yuting Fu, Ting Wang, Jianing Zhang, Min Yang, Zhaohuan Sun, Xiang Li, and Yongdong Li in Foodborne Pathogens and Disease 129 (2020) 528-534 https://www.liebertpub.com/doi/10.1089/fpd.2019.2751 and requested for retraction. The authors have subsequently admitted that Figs. 3A, 3D and 4B in this article were duplicated from Figs. 3A, 5A and 7B of the article published by Weidong Qian, Yuting Fu, Miao Liu, Ting Wang, Jianing Zhang, Min Yang, Zhaohuan Sun, Xiang Li and Yongdong Li in Antibiotics 8 (2019) 220 https://www.mdpi.com/2079-6382/8/4/220, which has been retracted https://www.mdpi.com/2079-6382/9/6/322. The authors have claimed that there were errors in the preparation of figures for three papers which had been submitted to multiple journals from August to October 2019. The authors have provided replacement images for Figs. 3 and 4 of this article, but these data did not resolve the concerns that call into question the reliability of the study findings. In light of these issues, the journal has decided to retract the article. The authors assert the findings, that ursolic acid exerted antibacterial activity against carbapenem-resistant Enterobacter cloacae, are nevertheless reliable.

Antimicrobial and Antibiofilm Activities of Citral Against Carbapenem-Resistant Enterobacter cloacae

Citral that is produced in the essential oils of plants is an isomeric mixture of geranial and neral. Few recent studies exhibited robust antibacterial activity of citral against several pathogens. However, little is reported about effects of citral on carbapenem-resistant Enterobacter cloacae (CREC). The purpose of this study was to assess antibacterial and antibiofilm activities of citral against CREC. Here, minimum inhibitory concentrations (MICs) of citral against CREC were determined by the agar dilution method. Antibacterial mode of citral against CREC was elucidated by evaluating changes in intracellular adenosine triphosphate (ATP) concentration, intracellular pH (pH_in), membrane potential, membrane integrity, and cell morphology. In addition, CREC cell damage within biofilms was examined by confocal laser scanning microscopy (CLSM). The results showed that the MIC of citral against CREC was 1000 μg/mL. Citral inhibited CREC growth and destroyed its cell membrane integrity, as measured by the decrease of intracellular ATP, pH, and membrane potential as well as distinctive deformation in cellular morphology. CLSM images demonstrated that citral could inactivate CREC cells within biofilms. These results revealed that citral exhibits potent antibacterial and antibiofilm activity against CREC, and thus has potential to be used as natural food preservatives to control CREC-associated infection spread.

Enterobacter Cloacae Device Endocarditis: Case Report, Scoping Study, and Guidelines Review

While traditionally an infection of the endocardial surface of heart valves, infective endocarditis (IE), can atypically present as infection of cardiac implantable electronic devices (CIED), including permanent pacemakers (PPM) or automatic implantable cardioverter-defibrillators (AICD). CIED endocarditis, similar to valvular IE, is generally caused by Gram-positive organisms such as Staphylococcus spp., most frequently S. Auerus, but is rarely caused by gram-negative bacteria, both HACEK and non-HACEK species. We present the case of Enterobacter cloacae CIED endocarditis. We also present a scoping study of previous case reports and case series highlighting the risk factors, surgical interventions, and mortality outcomes associated with E. Cloacae endocarditis. We also discuss the current guidelines and recommendations on antibiotic therapies for non-HACEK Gram-negative endocarditis and surgical management of infected CIED extraction and replacement.